Knight Therapeutics Inc. is making waves in the market with a notable gain.
Knight Therapeutics Inc. (GUD.TO) is experiencing a significant rise in its stock price, currently up by 4.43% to CA$9.67. This positive movement reflects investor confidence and anticipation ahead of its upcoming financial results.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Knight Therapeutics Inc.
GUD.TO
GUD.TO
Knight Therapeutics Inc.
WealthAwesomeMarket cap
$917.00M
P/E
155.7x
52W high
$10.17
52W low
$5.66
1W change
-6.18%
Beta
0.05
Analyst Price Targets
Based on analyst covering GUD
Wall Street analysts forecast GUD stock price to rise 6.1% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$9.83
+6.1% Upside
Current Price
C$9.26
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
23.8%
Annualized
90-Day Vol
30.1%
Annualized
Trend (90d)
+26.7%
Annualized drift
90d Mean
C$10.19
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$9.56 | C$8.80 – C$10.38 |
| 60 trading days | C$9.87 | C$8.78 – C$11.08 |
| 90 trading days | C$10.19 | C$8.83 – C$11.74 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: The recent surge in Knight Therapeutics' stock price suggests a bullish sentiment among investors, likely driven by upcoming earnings expectations and overall market conditions.
Stock up 4.43% to CA$9.67
Advertisement
Knight Therapeutics' market capitalization stands at approximately CA$917 million, indicating substantial investor interest and market confidence.
Bull case
Investors are feeling optimistic about Knight Therapeutics' growth potential, especially with the upcoming release of its second quarter 2026 results. These results could showcase strong performance and strategic advancements that excite the market.
Bear case
Even with the current upward trend, Knight Therapeutics faces challenges in a competitive pharmaceutical landscape. If the upcoming earnings call reveals disappointing results, it could quickly dampen investor sentiment.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
